Search PubMed⌕ Search

PubMed · 3283516

Immunoassays for IgG subclasses: quantitative and methodologic considerations.

Abstract

In summary I have tried to provide my own statement of the status quo in current efforts to develop quantitative and reliable immunoassays for IgG subclass proteins and antibodies. Some of the trends I have commented upon are summarized in Table III. First, monoclonal antibodies have clearly won the day for almost all IgG subclass work. Second, solid phase immunoassays are almost indispensable for most IgG subclass antibody assays in order to circumvent the problem of subclass antibody competitions for soluble antigen. Third, the "captured" antigen or antibody by insolubilized antisera has a number of demonstrated advantages over passive adsorption or covalent linkage, in terms of assay parallelism, sensitivity, and specificity. Fourth, subclass immune responses can only be compared directly if serum dilution curves are parallel. More attention is needed for further technical refinements to achieve this important goal. Finally, the value of absolute quantitation, that is specification of nominal value in terms of weight/volume units, is an important ultimate goal. Among the feasible approaches to this problem are solid phase elution techniques, myeloma protein based quantitation, and by comparison to a single allergen system where nominal values can be established by conventional techniques. We have come a long way since IgG subclasses were first recognized more than 25 years ago. We are not in a phase of rapid expansion of techniques which seek to quantify IgG subclass immune responses. Much work remains to be done, but the tools for ultimate success are, I believe, within our grasp.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

N F Adkinson. Immunoassays for IgG subclasses: quantitative and methodologic considerations.. https://doi.org/10.2500/108854188778984518

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

ZrO₂@C-based colorimetric/photothermal dual-mode immunosensor coupled with a novel monoclonal antibody for quantification of Aspergillus ochraceus biomass.

Aspergillus ochraceus contaminates agricultural products and produces nephrotoxic, carcinogenic ochratoxin A (OTA), posing severe food safety hazards. A dual-signal lateral flow immunochromatographic assay (dLFIA) based on ZrO₂@C nanoprobes was established for quantitative detection of A. ochraceus biomass. A novel monoclonal antibody (mAb 4B4) was prepared as the capture antibody to immobilize A. ochraceus mycelial lysate antigen on the test line, and a rabbit polyclonal antibody (pAb G2801) as the detection antibody to modify ZrO₂@C composites (synthesized via UiO-66 pyrolysis) into 200 nm colorimetric/photothermal nanoprobes. This dLFIA achieved limits of detection of 0.164 μg/mL (colorimetric) and 0.517 μg/mL (photothermal). This efficient and reliable method allows quantitative analysis of A. ochraceus biomass, which is suitable for routine monitoring of fungal contamination in agro-food matrices.

Antibodies, Monoclonal↗

Rituximab for lymphoproliferative disease prior to haematopoietic stem cell transplantation for X-linked severe combined immunodeficiency.

Lymphoproliferative disease (LPD) is a complication of congenital and acquired immunodeficiency states. There are a number of treatment options for LPD arising after haematopoietic stem cell or solid organ transplantation including reduction of immunosuppression, targeted therapies, such as the anti-CD20 monoclonal antibody, rituximab, and EBV specific cytotoxic lymphocytes. Treatment of LPD in children with congenital immunodeficiency syndromes remains unsatisfactory and is associated with a high mortality rate. We recently managed an infant found to have polymorphic LPD concurrent with X-linked severe combined immunodeficiency (SCID). Haematopoietic stem cell transplantation (HSCT) had to be deferred because of progressive LPD. Treatment with rituximab resulted in regression of the LPD following which the patient received a 5/6 HLA matched umbilical cord blood (UCB) transplant. The patient remains well 20 months following transplantation. Rituximab treatment may have a useful role in the control of LPD associated with congenital immunodeficiency prior to HSCT.

Antibodies, Monoclonal↗

Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus.

Opsoclonus-myoclonus (OM) is a paraneoplastic syndrome of probable autoimmune origin. Despite current therapies aimed at decreasing autoantibody formation, OM is difficult to control and may impact long-term neurologic outcome. We present a case of a 19-month-old patient who initially presented with OM, neuroblastoma and a constitutional cytogenetic abnormality t(5;12)(q11.2;q15). The patient's OM was recalcitrant to conventional therapies, but showed significant improvement following treatment with rituximab.

Antibodies, Monoclonal↗